TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05069220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MFBG
Description: Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Dotatate
Description: Patients with malignant PPGL and NB receive intravenously 68Ga-Dotatate followed by PET/CT after 40min of injection.
Study: NCT06480539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
Study: NCT05711251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity in Health Promotion
Description: During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
Study: NCT06754930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068 for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ametinib mesylate
Description: Ametinib mesylate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-102
Description: BP-102 for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin for injection.
Study: NCT06753539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILM forceps - membrane grasping
Description: grasping the epiretinal membrane at the starting location, using pinch peeling, is performed with an ILM forceps.
Study: NCT05478161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
Description: Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
Study: NCT06753539

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILM forceps - membrane grasping
Description: grasping the epiretinal membrane at the starting location, using pinch peeling, is performed with an ILM forceps.
Study: NCT05258357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted bone marrow biopsy
Description: After the usual landmark technique is performed and the potential site has been marked, the ultrasound machine fine tunes the drill site location. The probe is placed over the marked site in the transverse orientation. In this view, the location where the sacrum articulates near the ilium is visualized. The physician then searches for the location of the PSIS at its most superficial location, then the PSIS is centered. The probe is then rocked back and forth to determine the optimal drill angle.The skin is marked at the probe indicators on both long sides. In the sagittal orientation the PSIS is visualized and centered. The skin is then marked at the probe indicators on both long sides. The marker is then used to connect the marks, creating an X that marks the desired skin entry point

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark palpation bone marrow biopsy
Description: The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
Study: NCT05106296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily, throughout each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Study: NCT05563779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Control mode
Description: Volume Control mode for mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Control mode
Description: Pressure Control mode for mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Pressure Control mode
Description: Adaptive Pressure Control mode for mechanical ventilation
Study: NCT06468800

Intervention type: DEVICE
Group type: OTHER
Intervention: TRACMOTION
Description: Patients already scheduled for ESD will undergo an ESD procedure with the aid of the Tracmotion device
Study: NCT06014190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
Study: NCT06165835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breathing training
Description: Breathing training for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breathing training
Description: Breathing training for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breathing training
Description: Breathing training for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breathing training
Description: Breathing training for six weeks.
Study: NCT06409598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-immersive virtual reality home-based exercise.
Description: This intervention aims include some exercises in the form of games to facilitate and improve the upper limb functions and static balance from sitting and standing positions among chronic stroke survivors.
Study: NCT05002608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Insurance Navigation Tools Program
Description: The program will be delivered via videoconferencing by a navigator over a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Session 1- Insurance Plan Basics; Session 2- Your Plan in Relation to Legal Policy; Session 3- Navigating Your Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs; Session 5- Understanding Your Medical Bills.
Study: NCT05029791

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor biopsy
Description: 2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: 1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)
Study: NCT05320315

Intervention type: DEVICE
Group type: OTHER
Intervention: Foto Ultra ISDIN® Solar Allergy Fusion Fluid
Description: The tested MD is a very high protection sunscreen
Study: NCT05939960

Intervention type: DIAGNOSTIC_TEST
Intervention: CGT test
Description: GCT、PRP-CT、PPP-CT monitor

Intervention type: DIAGNOSTIC_TEST
Intervention: CGT test
Description: GCT、PRP-CT、PPP-CT monitor
Study: NCT06751966

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Product: Conventional third-line therapy
Description: Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-based peptide vaccine
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06752057

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-loaded DC vaccine
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT06752746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Multiple dose
Study: NCT06752772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart watch
Description: Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart watch
Description: Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart watch
Description: Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dashboard with nudging system
Description: Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard with nudging system
Description: Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Coach (DHC)
Description: Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.
Study: NCT06754956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The patient will receive two intravenous injections of the same gadoterate meglumine contrast agent.
Description: Each patient will undergo two different field strength HR-VWIs with enhancement, and on each occasion the patient will be injected with contrast DOTAREM (gadoterate meglumine) .
Study: NCT06752915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure application
Description: Acupressure massage will be applied to LI4, HT7, LU1 and ST 36 acupuncture points for 2 minutes.
Study: NCT06752993

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Muscle Strength Training (EMST-150)
Description: Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) used to exhale against a same-pressure load every exhalation for strengthening primarily the core muscles. The device pressure is adjusted according to PEmax and reliability/reproducibility has been demonstrated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) without physiological load. The sham device closely resembled the EMST device, with the only difference being that the pressure release valve was rendered nonfunctional by removing the spring. As a result, it exerted minimal to no physiological load on the targeted muscles.
Study: NCT06755788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: In the RT-CGM group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. RT-CGM monitoring will also be employed during surgery. A tablet in the operating room will be configured with low and high glucose alerts set at 3.9 mmol/L and 10.0 mmol/L, respectively. When an alarm is triggered, arterial blood gases will be rechecked, and glucose levels will be adjusted based on the arterial blood glucose results. If interstitial glucose values do not reach the intervention threshold, arterial blood gas measurements are recommended every 30 minutes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: In the control group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. CGM monitoring will also be employed during surgery, but the CGM interstitial glucose readings and alerts will be masked during the operation. The final intraoperative glucose management approach will be determined by the anesthesiologist, considering the patient's condition and surgical circumstances. The anesthesiologist can choose the intravenous insulin adjustment protocol we recommend.
Study: NCT06752681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY301
Description: DAY301 will be administered as IV infusion
Study: NCT06754085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florastamin[18F] Injection
Description: The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection.
Study: NCT06752473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSD-101
Description: Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
Study: NCT06752889

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group( 1): Control Group (pulpectomy using zic oxide eugenol based sealer Zical):
Description: Zinc oxide eugenol based sealer (Zical) will be mixed into a thick paste and packed into the pulp chamber to fill the canal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group ( 2) Experimental group modified 3-MIX-TATIN):
Description: Modified 3Mix-tatin will be prepared by mixing three commercially available antibiotics with simvastatin. This powder will be mixed with zinc oxide eugenol based sealer called Zical which will act as a carrier or vehicle to form a creamy paste of 3Mixtatin at the time of application
Study: NCT06752421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B: Low tidal volume
Description: In the LTV group, mechanical ventilation will be maintained with low tidal volume parameters after the aortic cross-clamp procedure. This intervention includes a tidal volume of 3-4 mL/kg, respiratory rate of 12-14 breaths/min, PEEP of 5-8 cmH₂O, and FiO₂ of 50%. Minute ventilation (MV) will not exceed 12 L, and the parameters are adjusted according to ideal body weight. This group is designed to evaluate the protective effects of low tidal volume ventilation during surgery.
Study: NCT06752200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.
Description: Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splints fabricated using a combined digital workflow using a conventional bite technique
Description: upper and lower arches will be scanned intraorally. The bite will be registered at centric by using rubber base bite registration material after patient deprogramming with Lucia jig. Then the bite will be scanned. The splint will be designed and printed in the same workflow as the intervention group.
Study: NCT06752239

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Modified delineation
Description: Modified delineation (MD) of cervical lymphatic drainage areas, sparing the common carotid artery within the clinical target volume (CTV)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard delineation
Description: Standard delineation
Study: NCT06754072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Keyboard (VK) System
Description: Participants underwent a 4-week training program comprising 12 one-hour sessions to enhance finger individuation and motor control using a virtual reality platform.
Study: NCT06755541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate in Combination With Ursodeoxycholic Acid
Description: Experimental: Fenofibrate 200 mg Capsules
Study: NCT06755827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation and self-monitoring to treat pediatric obesity
Description: Participants will attend telehealth group sessions once weekly and be asked to self-monitor their mood and health behaviors daily between sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants who are randomized to the control group will receive an online, one-time, self-led psychoeducation program with information about current daily sleep, diet, and physical activity recommendations (e.g., information about sleep hygiene, the food pyramid, and recommendations for 60 minutes of moderate-to-vigorous physical activity daily).
Study: NCT06753526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSAID
Description: For 1st group of patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine, 500 Mg Oral Capsule
Description: group 2by twice dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.4 mg QD
Description: group 3 by once per day
Study: NCT06753253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Description: Each arm will perform a 20-minute cycling intervention on an airdyne bike at different exercise intensity levels. Participants will perform the intervention three times over the course of one week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Description: Each arm will perform a 20-minute cycling intervention on an airdyne bike at different exercise intensity levels. Participants will perform the intervention three times over the course of one week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Description: Each arm will perform a 20-minute cycling intervention on an airdyne bike at different exercise intensity levels. Participants will perform the intervention three times over the course of one week.